Cargando…

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade

Immune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination of antiangiogenic agents and ICB has demonstrated efficacy in several cancers. To improve the mechanistic un...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabasum, Saba, Thapa, Dinesh, Giobbie-Hurder, Anita, Weirather, Jason L., Campisi, Marco, Schol, Pieter J., Li, Xiaoyu, Li, Jingjing, Yoon, Charles H., Manos, Michael P., Barbie, David A., Hodi, F. Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618652/ https://www.ncbi.nlm.nih.gov/pubmed/37728484 http://dx.doi.org/10.1158/2326-6066.CIR-23-0171

Ejemplares similares

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
por: Li, Xiaoyu, et al.
Publicado: (2023)

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2020)

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
por: Schoenfeld, Jonathan D., et al.
Publicado: (2019)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

EDIL3 and VEGF Synergistically Affect Angiogenesis in Endothelial Cells
por: Niu, Xuping, et al.
Publicado: (2023)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade
por: Miller, Peter G., et al.
Publicado: (2020)

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
por: Wright, Kyle T., et al.
Publicado: (2023)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Evaluation of Changes in the Expression Pattern of EDIL3 in Different Grades of Endometrial Cancer
por: Oplawski, Marcin, et al.
Publicado: (2019)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer
por: Ke, Bin, et al.
Publicado: (2023)

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

EDIL3 knockdown inhibits retinal angiogenesis through the induction of cell cycle arrest in vitro
por: Shen, Wei, et al.
Publicado: (2017)

Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma
por: Jeong, Dongjun, et al.
Publicado: (2017)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
por: Lee, Won Suk, et al.
Publicado: (2020)

Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation
por: Feng, Ming-Xuan, et al.
Publicado: (2014)

Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer
por: Jiang, Shu-Heng, et al.
Publicado: (2015)

EDIL3 influenced the αvβ3‐FAK/MEK/ERK axis of endothelial cells in psoriasis
por: Niu, Xuping, et al.
Publicado: (2022)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model
por: Kun, Zhang, et al.
Publicado: (2019)

Variants Within Genes EDIL3 and ADGRB3 are Associated With Divergent Fecal Egg Counts in Katahdin Sheep at Weaning
por: Becker, Gabrielle M., et al.
Publicado: (2022)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s2vhaf1bqa2qsggpdkp6g3er27